Standard Biotools Inc. LAB
We take great care to ensure that the data presented and summarized in this overview for STANDARD BIOTOOLS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LAB
View all-
Casdin Capital, LLC New York, NY61.9MShares$157 Million13.55% of portfolio
-
Viking Global Investors LP58.7MShares$149 Million0.61% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny14.4MShares$36.5 Million0.02% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$33.1 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$33.1 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.8.85MShares$22.5 Million0.02% of portfolio
-
Nikko Asset Management Americas, Inc.8.85MShares$22.5 Million0.24% of portfolio
-
Morgan Stanley New York, NY7.62MShares$19.3 Million0.0% of portfolio
-
Indaba Capital Management, L.P. San Francisco, CA7.36MShares$18.7 Million25.9% of portfolio
-
Tikvah Management LLC Charlotte, NC6.55MShares$16.6 Million5.59% of portfolio
Latest Institutional Activity in LAB
Top Purchases
Top Sells
About LAB
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Insider Transactions at LAB
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 23
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
100,000
+0.22%
|
$200,000
$2.6 P/Share
|
May 22
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
150,000
+0.33%
|
$300,000
$2.58 P/Share
|
May 21
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
350,000
+0.76%
|
$700,000
$2.56 P/Share
|
May 20
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
100,000
+0.22%
|
$200,000
$2.58 P/Share
|
May 20
2024
|
Hanjoon Alex Kim Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
333,333
+37.98%
|
-
|
May 20
2024
|
Jeffrey G. Black SVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+41.68%
|
-
|
May 20
2024
|
Michael Egholm President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000,000
+39.5%
|
-
|
May 17
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
352,072
+0.77%
|
$704,144
$2.56 P/Share
|
May 16
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+1.1%
|
$1,000,000
$2.54 P/Share
|
May 15
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+1.11%
|
$1,000,000
$2.57 P/Share
|
May 15
2024
|
Jeffrey G. Black SVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,779
-13.55%
|
$37,558
$2.54 P/Share
|
May 15
2024
|
Jeffrey G. Black SVP & Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
52,631
+27.52%
|
-
|
Apr 08
2024
|
Michael Egholm President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
102,564
-16.17%
|
$205,128
$2.71 P/Share
|
Apr 05
2024
|
Hanjoon Alex Kim Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,702
+25.09%
|
-
|
Apr 05
2024
|
Michael Egholm President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
212,126
+25.07%
|
-
|
Apr 04
2024
|
Hanjoon Alex Kim Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
70,183
+33.33%
|
-
|
Apr 04
2024
|
Michael Egholm President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
196,512
+31.77%
|
-
|
Mar 18
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Grant, award, or other acquisition
|
Indirect |
46,465,458
+46.24%
|
$92,930,916
$2.75 P/Share
|
Mar 05
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Direct |
1,403
+0.01%
|
$2,806
$2.62 P/Share
|
Mar 04
2024
|
Casdin Partners Master Fund, L.P. Director |
BUY
Open market or private purchase
|
Direct |
250,000
+2.13%
|
$500,000
$2.57 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 84.5M shares |
---|---|
Open market or private purchase | 2.3M shares |
Exercise of conversion of derivative security | 319K shares |
Other acquisition or disposition | 779K shares |
---|---|
Payment of exercise price or tax liability | 121K shares |